Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
作者信息
Laakso Markku, Rosenstock Julio, Groop Per-Henrik, Barnett Anthony H, Gallwitz Baptist, Hehnke Uwe, Tamminen Ilkka, Patel Sanjay, von Eynatten Maximilian, Woerle Hans-Juergen
机构信息
Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX.
出版信息
Diabetes Care. 2015 Feb;38(2):e15-7. doi: 10.2337/dc14-1684.
PMID:25614693
Abstract
摘要
Zotero 插件